Fulltext

Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study

Senn, C. ; Günther, B. ; Popp, A. ; Perrelet, R. ; Hans, D. ; Lippuner, K.

In: Osteoporosis International, 2014, vol. 25, no. 7, p. 1945-1951

Aggiungi alla tua lista
    Titre
    • Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study
    Auteur
    • Senn, C.. Department of Osteoporosis, Inselspital, Berne University Hospital and University of Berne, CH-3010, Berne, Switzerland
    • Günther, B.. Department of Osteoporosis, Inselspital, Berne University Hospital and University of Berne, CH-3010, Berne, Switzerland
    • Popp, A.. Department of Osteoporosis, Inselspital, Berne University Hospital and University of Berne, CH-3010, Berne, Switzerland
    • Perrelet, R.. Department of Osteoporosis, Inselspital, Berne University Hospital and University of Berne, CH-3010, Berne, Switzerland
    • Hans, D.. Center of Bone Disease, Bone and Joint Department, Lausanne University Hospital, Avenue Pierre Decker 4, 1011, Lausanne, VD, Switzerland
    • Lippuner, K.. Department of Osteoporosis, Inselspital, Berne University Hospital and University of Berne, CH-3010, Berne, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Osteoporosis International, 2014, vol. 25, no. 7, p. 1945-1951. Springer London
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:325308
    Summary
    Summary: Treatment effects over 2years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug. Introduction: The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from anteroposterior spine dual X-ray absorptiometry (DXA) scans. The potential role of TBS for monitoring treatment response with bone-active substances is not established. The aim of this study was to compare the effects of recombinant human 1-34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis. Methods: Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (N = 65) or quarterly intravenous IBN (N = 122) during 2years and with available LS BMD measurements at baseline and 2years after treatment initiation were compared. Results: Baseline characteristics (overall mean ± SD) were similar between groups in terms of age 67.9 ± 7.4years, body mass index 23.8 ± 3.8kg/m2, BMD L1-L4 0.741 ± 0.100g/cm2, and TBS 1.208 ± 0.100. Over 24months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6% ± 6.3 vs. +2.9% ± 3.3 and +4.3% ± 6.6 vs. +0.3% ± 4.1, respectively; P < 0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (r 2 = 0.04) with no correlation between the changes in BMD and TBS over 24months. Conclusions: In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.